Navigate the path from discovery to medicine
Plan, manage, and execute R&D programs with Orchestra
Clear alignment between cross-functional teams
Align trade-offs with resource constraints
Understand how program changes impact your entire portfolio
Efficacy studies
IND filing
Backup GMP production
In vivo GLP studies
Cell line development
Assay development
$3M and 18w
Safety/toxicity studies
Process development
Antibody optimization
GMP production
Navigate program complexity
Map critical dependencies across teams
Set portfolio strategy
Balance risk and opportunity across your pipeline
ORC-001
Oncology
Discovery
Preclinical
Clinical
Regulatory
Accelerate IND timeline
ORC-002
Autoimmune
Discovery
Preclinical
Clinical
Regulatory
Initiate backup to derisk ORC-002
ORC-002
Metabolic
Discovery
Preclinical
Clinical
Regulatory
Partner milestones at risk
ORC-001
Oncology
Accelerate IND timeline
ORC-002
Autoimmune
Initiate backup to derisk ORC-002
ORC-002
Metabolic
Partner milestones at risk
Deliver from bench to boardroom
Connect strategy to execution
Portfolio decisions
Tara · CEO
What can we do to make sure ORC-002 is ready for Phase 1 trials next year?
Overview and scenarios
Ashoka · Program Manager
Would we reach IND faster if we ran in vivo efficacy studies in parallel to our backup screens?
Timeline and resources
Trey · CMC Lead
Can we ramp up production so that we can increase trial enrollment?
Study readouts
Ky · Scientist
If this run is late, what are the downstream impacts? Should we change the plan to finish on time?
Experiments and data
Navigate program complexity
Map critical dependencies across teams
Clear alignment between cross-functional teams
Align trade-offs with resource constraints
Understand how program changes impact your entire portfolio
Efficacy studies
IND filing
Backup GMP production
In vivo GLP studies
Cell line development
Assay development
$3M and 18w
Safety/toxicity studies
Process development
Antibody optimization
GMP production
Deliver from bench to boardroom
Connect strategy to execution
Tara · CEO
What can we do to make sure ORC-002 is ready for Phase 1 trials next year?
Overview and scenarios
Portfolio decisions
Ashoka · Program Manager
Would we reach IND faster if we ran in vivo efficacy studies in parallel to our backup screens?
Trey · CMC Lead
Can we ramp up production so that we can increase trial enrollment?
Study readouts
Timelines and resources
Ky · Scientist
If this run is late, what are the downstream impacts? Should we adjust?
Experiments and data